daunorubicin + vincristine + prednisone + methotrexate + pegaspargase + mercaptopurine + cyclophosphamide + cytarabine + teniposide + thioguanine

This multi-agent chemotherapy combination regimen is investigated for the treatment of newly diagnosed acute lymphoblastic leukemia (ALL) in adults. The regimen, which includes induction, consolidation, and maintenance phases, was evaluated in a Phase 2 clinical trial (NCT00184041) sponsored by the University of Southern California. It incorporates ten distinct pharmacological agents with diverse mechanisms of action to target multiple aspects of leukemic cell proliferation and survival. The components include anthracyclines (daunorubicin), vinca alkaloids (vincristine), corticosteroids (prednisone), antifolates (methotrexate), pegylated enzymes (pegaspargase), thiopurine antimetabolites (mercaptopurine and thioguanine), alkylating agents (cyclophosphamide), nucleoside analogs (cytarabine), and topoisomerase II inhibitors (teniposide). The primary research focus of this specific combination was the safety and efficacy of substituting standard E. coli asparaginase with pegaspargase in an intensified post-remission setting for adult patients.

Other names

PEG-Asparaginase in Adult ALLintensified post-remission therapy containing PEG-asparaginase